| Document |
Document Title |
|
WO/2000/031094 |
This invention provides smooth muscle cell proliferation inhibitors of formula (I) having the structure (a) wherein Y is C or N; where n is 0 - 3; X is (II); or a pharmaceutically acceptable salt thereof.
|
|
WO/2000/031096 |
This invention provides smooth muscle cell proliferation inhibitors of formula (I), having structure (I), wherein X, R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿, R?7¿, R?8¿ and R?9¿ have the meaning given in the claims and description.
|
|
WO/2000/031059 |
The invention concerns compounds of formula (I) wherein: A represents R¿1? or(O)R¿1? where R¿1? represents an alkyl group comprising 1 to 30 carbon atoms, linear or branched, saturated or unsaturated, capable of being partly or totall...
|
|
WO/2000/030625 |
The invention relates to the use of a compound of formula (I) for the prophylaxis and therapy of infectious processes in humans and animals, which processes are induced by bacteria, fungi or parasites. The inventive compound is also used...
|
|
WO/2000/031092 |
This invention provides smooth muscle cell proliferation inhibitors of formula (I) having the structure or a pharmaceutically acceptable salt thereof.
|
|
WO/2000/029418 |
Inhibitors of glycosidases and glycosyltransferases, methods for their preparation and their identification are described.
|
|
WO/2000/029419 |
The present invention discloses chemiluminescent 1,2-dioxetane substrates capable of reacting with a neuraminidase to release optically detectable energy. These 1,2-dioxetanes have general formula (I), wherein Z is formula (II) and the v...
|
|
WO/2000/028064 |
The present invention relates to a compound named Vancoresmycin which is obtainable by cultivation of the microorganism HIL-006734 (DSM 12216), and to its pharmaceutically acceptable salts. The present invention further relates to a proc...
|
|
WO/2000/026370 |
Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands an...
|
|
WO/2000/026643 |
A detection device for three-dimensional tissue oxygen measurement in animals and humans comprising an array of optical fiber (12) effective for transmitting emitted phosphorescent light, and further comprising an array of phosphorescent...
|
|
WO/2000/026206 |
Disclosed is a method for producing compounds of formula (I), wherein R?1¿ represents H or (CH¿2?)¿m?OH, R?2¿ represents H or (CH¿2?)¿n?OH, R?3¿ represents H or (CH¿2?)¿p?OH and m, n and p represent 2-8 independently from one an...
|
|
WO/2000/026223 |
The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moities. These congeners show high activity $i(in vitro) against several tumor cell lines. The invention also descri...
|
|
WO/2000/025787 |
The present invention relates to pharmaceutical compositions containing poly(ADP-ribose) glucohydrolase inhibitors, also known as PARG inhibitors, and methods of using the same for inhibiting or decreasing free radical induced cellular e...
|
|
WO/2000/026399 |
Disclosed is a method for the production of compounds of formula (I), whereby m, n, p and R?1¿ have the meanings given in Claim 1. Said compounds can be used in an advantageous manner as food supplements. They are particularly suitable ...
|
|
WO/2000/024775 |
The present invention relates to the gene cluster for nogalamycin biosynthesis derived from $i(Streptomyces nogalater), and the use of the genes therein to obtain novel hybrid antibiotics for drug screening.
|
|
WO/2000/024753 |
The subject invention discloses materials and methods for the design, synthesis, and biochemical evaluation of chromogenic substrate compounds for sialidases of bacterial, viral, protozoa, and vertebrate (including humans) origin. In par...
|
|
WO/2000/024728 |
Biotransformation product of a fermentation with $i(Actinomyces) spp., (Merck Culture Collection MA7235) ATCC No. 202103 is an antifungal agent. This compound may be useful in the treatment of diseases caused by fungal pathogens such as ...
|
|
WO/2000/024405 |
Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on thi...
|
|
WO/2000/023406 |
The invention relates to a method for processing contaminated fatty alcohol mixtures, wherein: (b) the mixture is treated with an acid and (d) the fatty alcohol is then distilled from the residues. One particular advantage is that produc...
|
|
WO/2000/023453 |
A method for crystallizing doxorubicin hydrochloride from an aqueous solution thereof which comprises crystallizing under a condition comprising a temperature of 40 °C or higher, and an aggregate of doxorubicin hydrochloride crystals ha...
|
|
WO/2000/020428 |
One aspect of the present invention relates to differentially protected glycosyl phosphates. Another aspect of the present invention relates to the preparation of glycosyl phosphates from glycal precursors. In another aspect of the prese...
|
|
WO/2000/020392 |
The invention relates to aryl-substituted propanolamine derivatives and their pharmaceutically acceptable salts and functional derivatives. The invention relates to compounds of formula (I), wherein the radicals have the defined meanings...
|
|
WO/2000/018779 |
The invention relates to the use of tenside mixtures and a method for producing said mixtures which can be obtained by (a) acetalizing glycoses with fatty alcohols in a manner known per se and (b) subsequently ethoxylating the resulting ...
|
|
WO/2000/018410 |
Clinical utility of chemotherapy agents is limited by dose-dependent systemic toxicity and emergence of resistant tumor cell lines. The present invention provides derivatives of chemotherapeutic agents which can overcome these limitation...
|
|
WO/2000/017216 |
Carboxymethylgalactose derivatives represented by general formula (1); or salts thereof, which exhibit reactivity to selectins and are useful as inhibitors against selectin-related diseases such as various inflammations and cancerous met...
|
|
WO/2000/017195 |
The present invention is concerned with the compounds of formula (I), the $i(N)-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, it further relates to their use as a medicine.
|
|
WO/2000/015174 |
A use of bioflavonoid of formula (I) or a plant extract containing same for lowering the blood glucose level in a mammal.
|
|
WO/2000/015047 |
A pharmaceutical composition for treating or preventing an elevated blood lipid or glucose level-related disease such as hyperlipidemia, arteriosclerosis, angina pectoris, stroke, hepatic diseases and hyperglycemia in a mammal, which com...
|
|
WO/2000/014097 |
The invention relates to compounds of formula (I), wherein M, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, B5, B6, K1 and K2 have the meanings given in the description. Said compounds are novel, effective tryptase inhibitors.
|
|
WO/2000/011013 |
Modified 5'-unsubstituted 2' deoxyuridine residues appended with 3-aminopropyl,3-hydroxylpropyl and 3-aminopropyn-1-yl- sidechains have been used to study the effects of localized charges on duplex DNA oligomers. It has been shown that t...
|
|
WO/2000/008042 |
Nucleosidic monomers and oligomeric compounds prepared therefrom are provided which have increased nuclease resistance, substituent groups (such as 2'-aminooxy groups) for increasing binding affinity to complementary strand, and regions ...
|
|
WO/2000/008467 |
Compounds which bind to toxins associated with enteric bacterial infection, compositions including the compounds, methods for the neutralization of toxins in a patient, and methods for the diagnosis of bacterial and viral infections are ...
|
|
WO/2000/008038 |
Solid phase synthetic methods of forming sulfur-linked disaccharides and oligosccharides are described, wherein a saccharide or oligosaccharide bearing a protected thiol-group at the anomeric carbon is immobilized onto a solid support at...
|
|
WO/2000/006115 |
Sialyl oligosaccharides and derivatives useful for regulating inflammatory responses, and treating related disorders and conditions, and/or improving the texture or appearance of the skin, as well as topical pharmaceutical and cosmetic c...
|
|
WO/2000/004007 |
Dibenzazole compounds having general structure (I and II), wherein: R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6? are independently H or a substituent which aids in solubility of the compound or which provides a linker arm for linking the com...
|
|
WO/2000/004035 |
A method for forming a glycosidic linkage by: (a) contacting a glycoside bearing an anomeric sulfoxide group with a compound bearing a free hydroxyl group in the presence of an organic acid anhydride and a scavenger of sulfenyl esters; a...
|
|
WO/2000/002559 |
An aryl glucuronide of 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide, preferably an O-aryl glucuronide, as well as methods for the convenient synthesis of these aryl glucuronides, highly stable and low toxicity pharmaceutical composition co...
|
|
WO/2000/002568 |
The present invention is directed to double prodrugs containing polymeric-based transport forms. These polymeric prodrugs are preferably of formula (I) wherein: L is (a) or (b); B is H, OH, OSiR¿13?, a residue of an amine-containing tar...
|
|
WO/2000/001797 |
Transition metal complexes, referred to hereinafter as 'metalloligands', that catalyze the degradation of DNA and the cleavage of RNA at selected sites are provided. In one embodiment, the metalloligand has structure (I), wherein R1 is a...
|
|
WO/2000/001682 |
The invention relates to new paclitaxel derivatives showing an increased solubility in water. More particularly, the invention relates to glutarylpaclitaxel, glutarylpaclitaxel 6-aminohexanol glucuronide and to different amino acid deriv...
|
|
WO/2000/000205 |
Compositions comprising inositolphosphoglycans (IPGs) and ribose are disclosed, and their use in the prevention or treatment of ischaemic-reperfusion injury. This treatment increases the energy generating systems of cells by employing th...
|
|
WO/1999/067017 |
Compositions comprising alkoxylated lipophilic polyol compounds, e.g., ethoxylated, esterified methyl glucosides, are disclosed wherein at least 5 % of the polyol derivatives have about three moles of the lipophilic substituent per mole ...
|
|
WO/1999/067263 |
There are provided according to the invention, novel compounds of formula (I), wherein R?1¿, R?2¿, Z?1¿, Z?2¿, Z?3¿ and Z?4¿ are as defined in the specification, processes for preparing them, formulations containing them and their ...
|
|
WO/1999/067251 |
The invention relates to ethoxylated allyloligoglycosides of the formula (I): R?1¿O(CH¿2?CH¿2?O)¿n?[G]¿p?, wherein R?1¿ represents an allyl radical, G represents a sugar radical with 5-6 carbon atoms an n and independently represen...
|
|
WO/1999/067264 |
There are provided according to the invention novel compounds of formula (I), wherein R?1¿, R?2¿, R?3¿, Z?1¿, Z?2¿, Z?3¿ and Z?4¿ are as defined in the specification, processes for preparing them, formulations containing them and ...
|
|
WO/1999/067261 |
The invention concerns $g(a)-D-xylose compounds, as novel industrial products, corresponding to formula (I) wherein: X and Y represent, independently of each other, an oxygen atom or a sulphur atom; R¿1? represents a CN, CF¿3?, SO¿2?C...
|
|
WO/1999/066063 |
The invention is directed to mononucleosides and oligonucleotides that are conjugated to folic acid, related folates, antifolates and analogs thereof, and to non-nucleosidic folate conjugates. Methods for the preparation of nucleosidic a...
|
|
WO/1999/063940 |
Disclosed are multibinding compounds which inhibit H?+¿/K?+¿-ATPase, an enzyme which is involved in the control of acid secretion in the stomach. The multibinding compounds of this invention containing from 2 to 10 ligands covalently a...
|
|
WO/1999/063995 |
The invention relates to isoflavone esterified derivatives wherein the esterification is at one or more of carbon C4', C5, C6 and C7 positions to enhance solubility and bioavailability, which are useful as dietary supplements of natural ...
|
|
WO/1999/064054 |
Disclosed are multibinding compounds which inhibit topoisomerases which are essential enzymes in higher encaryotes for DNA replication and repair. The multibinding compounds of this invention containing from 2 to 10 ligands covalently at...
|
